

Major milestone for personalized medicine: MB Therapeutics becomes the world's first site authorized to manufacture pharmaceutical cartridges for 3D-printed medicines.

Montpellier (France) - MB Therapeutics, a French pioneer in personalized medicine, announces a major regulatory milestone. The French National Agency for medicines and health products safety (ANSM) has granted the company pharmaceutical establishment authorization to manufacture semi-solid pharmaceutical cartridges designed for the 3D printing of solid oral dosage forms.

This decision makes MB Therapeutics the first site in the world authorized to produce pharmaceutical cartridges dedicated to 3D printing medicines under official pharmaceutical manufacturer status.

A world first: industrial standardization serving tailor-made care

For over a century, medicine production has relied on standardized dosages. This approach presents major challenges, particularly for vulnerable populations such as pediatric and geriatric patients, whose needs for custom dosages and adapted oral forms often remain unmet.

The technological breakthrough brought by MB Therapeutics lies in the cartridge itself: a new standardized pharmaceutical product, manufactured in compliance with Good Manufacturing Practices (GMP).

It serves as the foundation for high-precision personalization directly at the patient's bedside:

- **A ready-to-use consumable:** An MB Therapeutics cartridge is a patented, airtight container prefilled in a GMP environment with a homogeneous pharmaceutical paste containing the active pharmaceutical ingredient (API) and carefully selected excipients.
- **Additive manufacturing (3D printing):** Serving as the true heart of the system, these pharmaceutical cartridges will enable MB Therapeutics 3D printers — designed to equip hospital pharmacies — to produce oral forms with the exact dosage required for each patient.
- **End-to-end safety and traceability:** This model guarantees medicine quality from cartridge production all the way to printing the oral dosage forms at the point of care.



Pharmaceutical ink cartridges slated for production in the Controlled Atmosphere Zone.

Photo credit: © MB Therapeutics

A commitment to quality and safety

Obtaining this authorization demonstrates that MB Therapeutics' application, including its quality management system and facilities, was deemed compliant with the requirements to grant pharmaceutical manufacturer status by the ANSM. Operational compliance with Good Manufacturing Practices at the facility is ongoing ahead of its official launch.

“Beyond precise dose adjustment and rapid availability in hospital pharmacies, 3D printing allows us to offer adapted galenic forms, such as personalized dispersible and orodispersible dosage forms,” states Dr. Manon Perez, Pharmacist and Quality Director at MB Therapeutics.



Tertiary packaging of pharmaceutical ink cartridges.
Photo credit: © MB Therapeutics

About MB Therapeutics

Based in Montpellier (France), MB Therapeutics is a pioneer start-up in the 3D printing of personalized medicines. Backed by over 10 years of expertise, its multidisciplinary team collaborates with key partners, including the Nimes University Hospital (*CHU de Nimes*). By developing unique formulations specifically adapted for children, the company positions itself at the forefront of personalized medicine, designing safe, effective, and tailor-made treatments.

More information at: www.mb-therapeutics.com

Press contact MB Therapeutics:

Stéphane Roulon
Co-Founder & CEO
stephane.roulon@mb-therapeutics.com
+33 6 21 50 44 82